The DOI matches its Crossref record; 178 of the 178 references it cites were found in a registry or an index.
Turning cold tumors into hot tumors by improving T-cell infiltration
Open accessAbstract
Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend on the infiltration of T cells capable of recognizing and killing tumor cells. ICIs are not effective in "cold tumors", which are characterized by the lack of T-cell infiltration. To realize the full potential of immunotherapy and solve this obstacle, it is essential to understand the drivers of T-cell infiltration into tumors. We present a critical review of our understanding of the mechanisms underlying "cold tumors", including impaired T-cell priming and deficient T-cell homing to tumor beds. "Hot tumors" with significant T-cell infiltration are associated with better ICI efficacy. In this review, we summarize multiple strategies that promote the transformation of "cold tumors" into "hot tumors" and discuss the mechanisms by which these strategies lead to increased T-cell infiltration. Finally, we discuss the application of nanomaterials to tumor immunotherapy and provide an outlook on the future of this emerging field. The combination of nanomedicines and immunotherapy enhances cross-presentation of tumor antigens and promotes T-cell priming and infiltration. A deeper understanding of these mechanisms opens new possibilities for the development of multiple T cell-based combination therapies to improve ICI effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Clinical development and potential of photothermal and photodynamic therapies for cancer
Li, X., Lovell, J. F., Yoon, J., & Chen, X. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0410-2 · Cited by 3,456
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
The entry of nanoparticles into solid tumours
Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., et al. (2020) · Nature Materials · doi:10.1038/s41563-019-0566-2 · Cited by 1,732
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
The gasdermins, a protein family executing cell death and inflammation
Broz, P., Pelegrín, P., & Shao, F. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0228-2 · Cited by 1,641
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,273
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Self-citationSalmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu, C., et al. (2016) · Nature · doi:10.1038/nature17412 · Cited by 1,010
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT
Malladi, S., Macalinao, D. G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.02.025 · Cited by 791
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P., Huang, S. C.-C., Fendt, S.-M., & Ho, P.-C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 733
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression
Gottfried, E., Kunz-Schughart, L. A., Ebner, S., Mueller-Klieser, W., Hoves, S., Andreesen, R., Mackensen, A., & Kreutz, M. (2006) · Blood · doi:10.1182/blood-2005-05-1795 · Cited by 729
Comprehensive understanding of magnetic hyperthermia for improving antitumor therapeutic efficacy
Liu, X., Zhang, Y., Wang, Y., Zhu, W., Li, G., Ma, X., Zhang, Y., Chen, S., Tiwari, S., Shi, K., et al. (2020) · Theranostics · doi:10.7150/thno.40805 · Cited by 719
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 698
An orally available non-nucleotide STING agonist with antitumor activity
Pan, B.-S., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., et al. (2020) · Science · doi:10.1126/science.aba6098 · Cited by 694
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.117 · Cited by 665
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Self-citationMechanisms of Leukocyte Transendothelial Migration
Muller, W. A. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130224 · Cited by 625
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
Pilon-Thomas, S., Kodumudi, K. N., El-Kenawi, A. E., Russell, S., Weber, A. M., Luddy, K., Damaghi, M., Wojtkowiak, J. W., Mulé, J. J., Ibrahim-Hashim, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1743 · Cited by 593
Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Bockorny, B., Semenisty, V., Macarulla, T., Borazanci, E., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 557
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Schalper, K. A., Carleton, M., Zhou, M., Chen, T., Feng, Y., Huang, S.-P., Walsh, A. M., Baxi, V., Pandya, D., Baradet, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0856-x · Cited by 548
Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2008) · Nature Medicine · doi:10.1038/nm1699 · Cited by 546
Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic
Chin, E. N., Yu, C., Vartabedian, V. F., Jia, Y., Kumar, M., Gamo, A. M., Vernier, W., Ali, S. H., Kissai, M., Lazar, D. C., et al. (2020) · Science · doi:10.1126/science.abb4255 · Cited by 546
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1327 · Cited by 535
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., & Li, C.-Y. (2020) · Nature · doi:10.1038/s41586-020-2911-7 · Cited by 490
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Holmgaard, R. B., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 482
Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469
Mutations and mechanisms of WNT pathway tumour suppressors in cancer
Bugter, J. M., Fenderico, N., & Maurice, M. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00307-z · Cited by 466
Tumor-Associated Macrophages Press the Angiogenic Switch in Breast Cancer
Lin, E. Y., & Pollard, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0912 · Cited by 463
Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity
Wang, J. X., Choi, S. Y. C., Niu, X., Kang, N., Xue, H., Killam, J., & Wang, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218363 · Cited by 460
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Combining Nanomedicine and Immunotherapy
Shi, Y., & Lammers, T. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00148 · Cited by 457
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Yuen, K. C., Liu, L.-F., Gupta, V., Madireddi, S., Keerthivasan, S., Li, C., Rishipathak, D., Williams, P., Kadel, E. E., Koeppen, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0860-1 · Cited by 429
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Li, Y., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 399
Immune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
Rao, L., Wu, L., Liu, Z., Tian, R., Yu, G., Zhou, Z., Yang, K., Xiong, H.-G., Zhang, A., Yu, G.-T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18626-y · Cited by 376
Self-citationRed blood cell–derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy
Han, X., Shen, S., Fan, Q., Chen, G., Archibong, E., Dotti, G., Liu, Z., Gu, Z., & Wang, C. (2019) · Science Advances · doi:10.1126/sciadv.aaw6870 · Cited by 349
Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J., Barve, M., Daniels, G. A., Wong, D. J., Schmidt, E. V., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0280 · Cited by 337
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Reisländer, T., Groelly, F. J., & Tarsounas, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.026 · Cited by 314
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302
Ni, Q., Zhang, F., Liu, Y., Wang, Z., Yu, G., Liang, B., Niu, G., Su, T., Zhu, G., Lu, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaw6071 · Cited by 281
Self-citationLuo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275
Mizukoshi, E., Yamashita, T., Arai, K., Sunagozaka, H., Ueda, T., Arihara, F., Kagaya, T., Yamashita, T., Fushimi, K., & Kaneko, S. (2013) · Hepatology · doi:10.1002/hep.26153 · Cited by 273
Nagarsheth, N., Peng, D., Kryczek, I., Wu, K., Li, W., Zhao, E., Zhao, L., Wei, S., Frankel, T., Vatan, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1938 · Cited by 271
Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy
Zhao, P., Wang, M., Chen, M., Chen, Z., Peng, X., Zhou, F., Song, J., & Qu, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120142 · Cited by 263
Interferons and Their Stimulated Genes in the Tumor Microenvironment
Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 255
Colbeck, E. J., Ager, A., Gallimore, A., & Jones, G. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01830 · Cited by 252
Zhang, Y., Li, N., Suh, H., & Irvine, D. J. (2018) · Nature Communications · doi:10.1038/s41467-017-02251-3 · Cited by 248
Chao, Y., Liang, C., Tao, H., Du, Y., Wu, D., Dong, Z., Jin, Q., Chen, G., Xu, J., Xiao, Z., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz4204 · Cited by 237
The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis
Kingston, D., Schmid, M. A., Onai, N., Obata-Onai, A., Baumjohann, D., & Manz, M. G. (2009) · Blood · doi:10.1182/blood-2009-02-206318 · Cited by 236
Hypoxia and acidosis: immune suppressors and therapeutic targets
Damgaci, S., Ibrahim‐Hashim, A., Enriquez‐Navas, P. M., Pilon‐Thomas, S., Guvenis, A., & Gillies, R. J. (2018) · Immunology · doi:10.1111/imm.12917 · Cited by 231
Wu, D., Wang, S., Yu, G., & Chen, X. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202010281 · Cited by 228
Peske, J. D., Thompson, E. D., Gemta, L., Baylis, R. A., Fu, Y.-X., & Engelhard, V. H. (2015) · Nature Communications · doi:10.1038/ncomms8114 · Cited by 227
Liu, X., Zheng, J., Sun, W., Zhao, X., Li, Y., Gong, N., Wang, Y., Ma, X., Zhang, T., Zhao, L.-Y., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b01979 · Cited by 226
Maatouk, D. M., Kellam, L. D., Mann, M. R. W., Lei, H., Li, E., Bartolomei, M. S., & Resnick, J. L. (2006) · Development · doi:10.1242/dev.02500 · Cited by 221
Lai, J., Mardiana, S., House, I. G., Sek, K., Henderson, M. A., Giuffrida, L., Chen, A. X. Y., Todd, K. L., Petley, E. V., Chan, J. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0676-7 · Cited by 219
Zhang, Q., Wei, W., Wang, P., Zuo, L., Li, F., Xu, J., Xi, X., Gao, X., Ma, G., & Xie, H.-Y. (2017) · ACS Nano · doi:10.1021/acsnano.7b04955 · Cited by 210
Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
Sek, K., Mølck, C., Stewart, G. D., Kats, L., Darcy, P. K., & Beavis, P. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123837 · Cited by 204
Zhang, Y., Ma, S., Liu, X., Xu, Y., Zhao, J., Si, X., Li, H., Huang, Z., Wang, Z., Tang, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202007293 · Cited by 199
Prendergast, G. C., Mondal, A., Dey, S., Laury-Kleintop, L. D., & Muller, A. J. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.11.005 · Cited by 196
CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis
Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117534 · Cited by 178
Rios-Doria, J., Durham, N., Wetzel, L., Rothstein, R., Chesebrough, J., Holoweckyj, N., Zhao, W., Leow, C. C., & Hollingsworth, R. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.004 · Cited by 174
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Georganaki, M., van Hooren, L., & Dimberg, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03081 · Cited by 172
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
Seliger, B. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0515-4 · Cited by 165
PAK4 inhibition improves PD-1 blockade immunotherapy
Abril-Rodríguez, G., Torrejon, D. Y., Liu, W., Zaretsky, J. M., Nowicki, T. S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M. J., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0003-0 · Cited by 164
Singer, K., Kastenberger, M., Gottfried, E., Hammerschmied, C. G., Büttner, M., Aigner, M., Seliger, B., Walter, B., Schlösser, H., Hartmann, A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25543 · Cited by 160
Nanoparticle‐Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses
Nuhn, L., De Koker, S., Van Lint, S., Zhong, Z., Catani, J. P., Combes, F., Deswarte, K., Li, Y., Lambrecht, B. N., Lienenklaus, S., et al. (2018) · Advanced Materials · doi:10.1002/adma.201803397 · Cited by 159
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 159
McDonald, P. C., Chafe, S. C., & Dedhar, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00027 · Cited by 156
Ritter, C., Fan, K., Paschen, A., Hadrup, S. R., Ferrone, S., Nghiem, P., Ugurel, S., Schrama, D., & Becker, J. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-02608-0 · Cited by 155
Sun, Y. L., Zhang, Y., Gao, Y., Wang, P., He, G., Blum, N. T., Lin, J., Liu, Q., Wang, X., & Huang, P. (2020) · Advanced Materials · doi:10.1002/adma.202004481 · Cited by 154
Zheng, Y., Tang, L., Mabardi, L., Kumari, S., & Irvine, D. J. (2017) · ACS Nano · doi:10.1021/acsnano.7b00078 · Cited by 153
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
Russell, L., Peng, K. W., Russell, S. J., & Díaz, R. M. (2019) · BioDrugs · doi:10.1007/s40259-019-00367-0 · Cited by 148
Brabletz, T., Pfeuffer, I., Schorr, E., Siebelt, F., Wirth, T., & Serfling, E. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.2.1155-1162.1993 · Cited by 146
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1409 · Cited by 146
Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity
Seth, P., Csizmadia, E., Hedblom, A., Vuerich, M., Xie, H., Li, M., Longhi, M. S., & Wegiel, B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2938 · Cited by 144
Li, J., Anraku, Y., & Kataoka, K. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004180 · Cited by 142
Cong, Z., Zhang, L., Ma, S.-Q., Lam, K. S., Yang, F.-F., & Liao, Y. (2020) · ACS Nano · doi:10.1021/acsnano.9b08434 · Cited by 141
Human mononuclear phagocyte system reunited
Haniffa, M. A., Bigley, V., & Collin, M. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.05.004 · Cited by 134
Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release
Szot, C. S., Saha, S., Zhang, X. M., Zhu, Z., Hilton, M. B., Morris, K., Seaman, S., Dunleavey, J. M., Hsu, K.-S., Yu, G., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120481 · Cited by 134
Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131
Siska, P. J., Singer, K., Evert, K., Renner, K., & Kreutz, M. P. (2020) · Immunological Reviews · doi:10.1111/imr.12846 · Cited by 131
Xiao, Q., Wu, J., Wang, W.-J., Chen, S., Zheng, Y., Yu, X., Meeth, K., Sahraei, M., Bothwell, A. L. M., Chen, L., et al. (2018) · Nature Medicine · doi:10.1038/nm.4496 · Cited by 130
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 126
Yamazaki, T., Buqué, A., Ames, T. D., & Galluzzi, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1721810 · Cited by 123
Directing Traffic: How to Effectively Drive T Cells into Tumors
Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 113
Zhang, N., Song, J., Liu, Y., Liu, M., Zhang, L., Sheng, D., Deng, L., Yi, H., Wu, M., Zheng, Y., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.036 · Cited by 104
Self-citationQi, X., Yang, M. J., Ma, L., Sauer, M. A., Avella, D. M., Kaifi, J. T., Bryan, J. N., Cheng, K., Staveley-O’Carroll, K. F., Kimchi, E. T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001038 · Cited by 104
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Young, A., Ngiow, S. F., Madore, J., Reinhardt, J., Landsberg, J., Chitsazan, A., Rautela, J., Bald, T., Barkauskas, D. S., Ahern, E. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0393 · Cited by 103
McGrail, D. J., Federico, L., Li, Y., Dai, H., Lu, Y., Mills, G. B., Yi, S. S., Lin, S., & Sahni, N. (2018) · Nature Communications · doi:10.1038/s41467-018-03730-x · Cited by 103
The cytotoxic T lymphocyte immune synapse at a glance
Dieckmann, N. M. G., Frazer, G. L., Asano, Y., Stinchcombe, J. C., & Griffiths, G. M. (2016) · Journal of Cell Science · doi:10.1242/jcs.186205 · Cited by 100
Ottensmeier, C. H. H., Perry, K. L., Harden, E. L., Stasakova, J., Jenei, V., Fleming, J. C., Wood, O., Woo, J., Woelk, C. H., Thomas, G. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3121 · Cited by 99
Bai, S., Yang, L., Wang, Y., Zhang, T., Fu, L., Yang, S., Wan, S., Wang, S., Jia, D., Li, B., et al. (2020) · Small · doi:10.1002/smll.202000214 · Cited by 95
Self-citationIlovitsh, T., Feng, Y., Foiret, J. L., Kheirolomoom, A., Zhang, H., Ingham, E. S., Ilovitsh, A., Tumbale, S. K., Fite, B. Z., Wu, B., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914906117 · Cited by 94
Lee, J. W., Zhang, Y. X., Eoh, K. J., Sharma, R., Sanmamed, M. F., Wu, J. Q., Choi, J., Park, H. S., Iwasaki, A., Kaftan, E. J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.004 · Cited by 84
Penetrable Nanoplatform for “Cold” Tumor Immune Microenvironment Reeducation
Chen, Q., He, Y., Wang, Y., Li, C., Zhang, Y., Guo, Q., Zhang, Y., Chu, Y., Liu, P., Chen, H., et al. (2020) · Advanced Science · doi:10.1002/advs.202000411 · Cited by 82
Chavez, M., Silvestrini, M. T., Ingham, E. S., Fite, B. Z., Mahakian, L. M., Tam, S. M., Ilovitsh, A., Monjazeb, A. M., Murphy, W. J., Hubbard, N. E., et al. (2018) · Theranostics · doi:10.7150/thno.25613 · Cited by 80
Perspectives on Recent Progress in Focused Ultrasound Immunotherapy
Sheybani, N., & Price, R. J. (2019) · Theranostics · doi:10.7150/thno.37131 · Cited by 68
Shimabukuro‐Vornhagen, A., Draube, A., Liebig, T. M., Rothe, A., Kochanek, M., & von Bergwelt‐Baildon, M. S. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-47 · Cited by 65
Carmona-Rodríguez, L., Martínez-Rey, D., Fernández-Aceñero, M. J., González-Martín, A., Paz-Cabezas, M., Rodríguez-Rodríguez, N., Pérez-Villamil, B., Sáez, M. E., Díaz-Rubio, E., Mira, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000432 · Cited by 51
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors
Brooks, E. D., Schoenhals, J. E., Tang, C. Z., Micevic, G., Gomez, D. R., Chang, J. Y., & Welsh, J. W. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000210 · Cited by 50
Wu, D., Wang, S., Yu, G., & Chen, X. S. (2020) · Angewandte Chemie · doi:10.1002/ange.202010281 · Cited by 45
Cited by
Nanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,168
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Metadata
- Authors
- Liu, Y.-T., & Sun, Z.-J.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2021
- Volume
- 11
- Issue
- 11
- Pages
- 5365-5386
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3137422569
- Cited by
- 827
- References
- 178
- FWCI
- 43.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.